Asset Planning Services Inc. LA ADV cut its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,614 shares of the biopharmaceutical company’s stock after selling 170 shares during the quarter. Bristol-Myers Squibb accounts for 3.0% of Asset Planning Services Inc. LA ADV’s portfolio, making the stock its 25th largest position. Asset Planning Services Inc. LA ADV’s holdings in Bristol-Myers Squibb were worth $3,514,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. American National Bank lifted its position in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 508 shares in the last quarter. Welch Investments LLC lifted its position in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 79 shares in the last quarter. Crestwood Advisors Group LLC purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth approximately $116,000. Blue Chip Partners Inc. lifted its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 17 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 60 shares in the last quarter. 68.80% of the stock is owned by institutional investors.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.
Shares of Bristol-Myers Squibb Company (BMY) traded down 0.33% during midday trading on Friday, hitting $62.48. 10,407,558 shares of the stock traded hands. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $63.47. The company has a market capitalization of $102.46 billion, a PE ratio of 22.82 and a beta of 1.18. The firm’s 50 day moving average price is $58.56 and its 200 day moving average price is $55.95. Bristol-Myers Squibb also was the target of unusually large options trading on Thursday. Traders acquired 781 put options on the company. This is an increase of 117% compared to the average volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.69 EPS. Analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is presently 56.73%.
A number of analysts have recently issued reports on the stock. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Credit Suisse Group restated a “hold” rating on shares of Bristol-Myers Squibb in a report on Friday, September 8th. Jefferies Group LLC increased their price objective on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday. Finally, Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price objective on the stock in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $62.66.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Stake Decreased by Asset Planning Services Inc. LA ADV” was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/bristol-myers-squibb-company-bmy-shares-sold-by-asset-planning-services-inc-la-adv/1566777.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.